BFLY

ANALYST NOTE: BFLY (Butterfly Network, Inc.) Date: 2026-06-20 Current Price: $8.90

1. Structural Readiness

State: Context-only Conservative Entry: — Current Price: $8.90 Extension: — ATR at Breakout: — ATR Current: 7.3% (Very High) Pivot Strength: —

Analysis:

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Secular Exposure: None Named

At this date, BFLY is not anchored to a specific named macro or secular thesis in the current context. It is a TACTICAL, setup-led name. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the immediate business fundamentals provided in the recent earnings data. There is no external macro narrative to lean on; the conviction must derive entirely from the company's execution of its growth plan and the structural integrity of the price action.

3. The Business

Company Overview: Butterfly Network, Inc. is a digital health business transforming care through portable, semiconductor-based ultrasound technology, intuitive software, services, and educational offerings. The company markets and sells the Butterfly system (probes, accessories, and software subscriptions) to healthcare systems, physicians, and providers via a direct sales force, distributors, and eCommerce channels.

Business Model & Financials (as of Q1 2026):

• Revenue Growth: The company reported strong financial performance in 2026. For the full year 2025, total revenue was $97.6 million, up from $82.1 million in 2024. Management reaffirmed guidance for 2026, expecting revenue between $117 million and $121 million, representing a 20% to 24% increase over 2025.
• Product Mix & Pricing: The portfolio includes the Butterfly iQ+ (approx. $2,700) and the newer Butterfly iQ3 (approx. $3,900), which features the P4.3 chip and 3D imaging. Units fulfilled increased by 4.9% (234 units) in Q1 2026 compared to the prior year, driven by international distributor and veterinary channels (specifically the iQ3 Vet probe).
• Software & Services: This segment is a key growth driver. Software and other services revenue increased by 68.2% year-over-year in Q1 2026, primarily driven by Embedded partnerships. Management expects the annual revenue mix to shift further toward software and services as adoption grows.
• Backlog & Visibility: As of March 31, 2026, the Company had $91.4 million in remaining performance obligations. Management expects to recognize 55% of this backlog as revenue in the next twelve months, providing near-term revenue visibility.
• Commercial Expansion: Management expects the first commercial agreement for its HomeCare Services Business to be signed in the first half of 2026, with nurse training beginning in the third quarter. This program targets reducing readmissions for congestive heart failure patients.
• Balance Sheet: The company maintains a strong balance sheet with $91.4 million in cash and cash equivalents as of March 31, 2026 (down from $99.6 million at year-end 2025). Management states that existing cash and cash flows from operations are sufficient to meet liquidity and capex requirements for at least the next 12 months.

4. Archetype and Conviction

Archetype: Growth Leader / Margin Inflector Rationale: BFLY fits the Growth Leader archetype with a distinct Margin Inflector characteristic. The business is transitioning from a pure hardware play to a hybrid hardware-software model. The 68.2% surge in software revenue and the 69% gross margin reported in Q1 2026 indicate a successful shift toward higher-margin recurring revenue streams. The introduction of the iQ3 and the "Butterfly Move" cart system (launched Nov 2025) demonstrates product iteration and market expansion.

Conviction Stack:

• Thesis Strength: Low (Tactical only, no macro anchor).
• Evidence Quality: High. The evidence base is robust, with clear guidance, specific backlog numbers, and detailed product rollout data from Q1 2026 earnings and 2025 10-K filings.
• Structural Quality: Moderate to High. The forming coil indicates a base has been built, but the "Very High" ATR (7.3%) introduces execution risk regarding price stability.
• Setup Readiness: Partial. The setup is "Forming," meaning it is a watch-list candidate but not yet a confirmed entry.
• Rerating Potential: Moderate. The rerating potential depends on the successful execution of the HomeCare commercial agreements and the continued expansion of the Embedded partner network (now at 30 partners).

5. Invalidation, Strengthening, and Gaps

What Would Invalidate:

• Fundamental: A significant miss on the reaffirmed 2026 revenue guidance ($117M–$121M) or a failure to secure the expected first commercial HomeCare agreement in H1 2026.
• Liquidity: A statement indicating that cash on hand is insufficient to fund operations for the next 12 months, contradicting current management expectations.

What Would Strengthen:

• Technical: A confirmed breakout above the resistance level with volume, transitioning the coil to "Confirmed-Active."
• Fundamental: Announcement of the first major HomeCare commercial agreement and the successful training of nurses for the Q3 rollout.
• Product: Further FDA clearances for the Blind Sweep AI tool or new Embedded partners joining the portfolio.

Gaps in Evidence:

• Profitability Timeline: While the company reports the "lowest first quarter net loss since going public," there is no specific evidence in the provided text regarding the timeline to GAAP profitability or the specific path to positive free cash flow beyond the 12-month liquidity runway.
• Competitive Moat: The evidence highlights product features and partnerships but does not explicitly quantify competitive advantages against traditional ultrasound giants or other digital health entrants in the $100B+ home care market.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 1) Reaffirmed 2026 revenue guidance of $117M-$121M (20-24% growth); 2) Software revenue up 68.2% YoY indicating margin inflection; 3) $91.4M backlog with 55% recognition expected in next 12 months. Key risks: 1) Very high ATR (7.3%) creates execution volatility and potential for false breakouts; 2) Dependence on unconfirmed commercial HomeCare agreements for next growth phase; 3) No named secular thesis to support valuation during market downturns. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "Forming" state and elevated volatility. Expected path: Management expects revenue growth to continue through 2026, with the first HomeCare commercial agreement signed in H1 2026 and nurse training commencing in Q3, driving probe utilization and system adoption. Expected horizon: 6 to 12 months for the setup to resolve (breakout or invalidation) and for the commercial agreements to materialize.